An Explanation of the Controversies Surrounding Aducanumab

Video

Despite the FDA's approval of aducanumab for the treatment of Alzheimer disease with mild cognitive impairments, it has been surrounded by questions.

Despite the FDA's approval of aducanumab for the treatment of Alzheimer disease with mild cognitive impairments, it has been surrounded with controversies. In an interview with Pharmacy Times, Pamela Spicer, MS, senior analyst with Datamonitor at Informa Pharma Intelligence, outlined the various concerns raised by experts, and the responses of patient advocacy groups.

Findings from 2 pivotal phase 3 trials noted decreases in amyloid plaque in the brain, although they had differing results in cognitive impairments. Based on these findings, the FDA Advisory Committee declined to approve aducanumab in 2020, although it was reconsidered and later approved in 2021 despite some experts' concerns.

Related Videos
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
pharmacy oncology, Image Credit: © Konstantin Yuganov - stock.adobe.com
Mayo Clinic oncology pharmacy
Testicular cancer and prostate cancer concept. | Image Credit: kenchiro168 - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Bottle and scattered pills on color background, top view | Image Credit: New Africa - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.